FI930206A0 - Adoptiv immunoterapi med interleukin-7 - Google Patents

Adoptiv immunoterapi med interleukin-7

Info

Publication number
FI930206A0
FI930206A0 FI930206A FI930206A FI930206A0 FI 930206 A0 FI930206 A0 FI 930206A0 FI 930206 A FI930206 A FI 930206A FI 930206 A FI930206 A FI 930206A FI 930206 A0 FI930206 A0 FI 930206A0
Authority
FI
Finland
Prior art keywords
lymphoid cells
immunotherapy
adoptiv
interleukin
med
Prior art date
Application number
FI930206A
Other languages
English (en)
Other versions
FI930206A (fi
FI105045B (fi
Inventor
David H Lynch
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of FI930206A0 publication Critical patent/FI930206A0/fi
Publication of FI930206A publication Critical patent/FI930206A/fi
Application granted granted Critical
Publication of FI105045B publication Critical patent/FI105045B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI930206A 1990-07-26 1993-01-19 Menetelmä sytolyyttisten T-lymfosyyttien muodostamiseksi FI105045B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/559,001 US5229115A (en) 1990-07-26 1990-07-26 Adoptive immunotherapy with interleukin-7
US55900190 1990-07-26
PCT/US1991/004919 WO1992001459A1 (en) 1990-07-26 1991-07-12 Adoptive immunotherapy with interleukin-7
US9104919 1991-07-12

Publications (3)

Publication Number Publication Date
FI930206A0 true FI930206A0 (fi) 1993-01-19
FI930206A FI930206A (fi) 1993-01-19
FI105045B FI105045B (fi) 2000-05-31

Family

ID=24231881

Family Applications (1)

Application Number Title Priority Date Filing Date
FI930206A FI105045B (fi) 1990-07-26 1993-01-19 Menetelmä sytolyyttisten T-lymfosyyttien muodostamiseksi

Country Status (16)

Country Link
US (1) US5229115A (fi)
EP (1) EP0540599B1 (fi)
JP (1) JP3825467B2 (fi)
AT (1) ATE161180T1 (fi)
AU (1) AU646881B2 (fi)
CA (1) CA2087525C (fi)
DE (1) DE69128476T2 (fi)
DK (1) DK0540599T3 (fi)
ES (1) ES2112860T3 (fi)
FI (1) FI105045B (fi)
GR (1) GR3026358T3 (fi)
IE (1) IE912486A1 (fi)
IL (1) IL98957A (fi)
NO (1) NO930243L (fi)
NZ (1) NZ239113A (fi)
WO (1) WO1992001459A1 (fi)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714585A (en) * 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
US5728388A (en) * 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US5474769A (en) * 1991-03-08 1995-12-12 Sterling Winthrop Inc. Treatment of microbial infection by monocyte stimulation with interleukin-7
AU6358994A (en) * 1993-03-02 1994-09-26 David S. Terman Method of cancer treatment
US20020127201A1 (en) * 1994-07-01 2002-09-12 Dana-Farber Cancer Institute. Methods for inhibiting T cell responses by manipulating a common cytokine receptor gamma-chain
US6576236B1 (en) * 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US6207147B1 (en) * 1996-10-11 2001-03-27 The Regents Of The University Of California Cancer immunotherapy using tumor cells combined with mixed lymphocytes
US5627070A (en) * 1995-07-26 1997-05-06 Celltherapy, Inc. Cell growing device for in vitro cell population expansion
US20020182730A1 (en) * 1995-07-26 2002-12-05 Micheal L. Gruenberg Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
DE69723230T2 (de) 1996-01-17 2004-05-27 Imperial College Innovations Ltd. Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
FR2745185B1 (fr) * 1996-02-28 1998-05-15 Sanofi Sa Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant
US5981472A (en) * 1997-02-21 1999-11-09 Dx/Ibr Corporation Methods for treating diseases
AU2873999A (en) 1998-02-24 1999-09-06 Sisters Of Providence In Oregon Compositions containing an OX-40 receptor binding agent or nucleic acid encoding the same and methods for enhancing antigen-specific immune response
AU2001296962A1 (en) 2000-09-29 2002-04-08 Schering Corporation Pegylated interleukin-10
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
CA2698079C (en) 2001-02-20 2015-01-13 Ortho-Mcneil Pharmaceutical, Inc. A cell therapy method for the treatment of tumors
FR2821947B1 (fr) * 2001-03-12 2003-05-16 Canon Kk Procede et dispositif de validation de parametres definissant une image
DE10132502A1 (de) * 2001-07-05 2003-01-23 Gsf Forschungszentrum Umwelt Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen
US20030134341A1 (en) * 2001-09-19 2003-07-17 Medcell Biologics, Llc. Th1 cell adoptive immunotherapy
US20030134415A1 (en) * 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
US20050095230A1 (en) * 2001-11-22 2005-05-05 Yoo Nae C. Interleukin-2 gene transferred lymphokine activated killer cells
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
JP2009511637A (ja) 2005-10-17 2009-03-19 スローン−ケターリング インスティチュート フォー キャンサー リサーチ Ｈｌａクラスｉｉ結合ｗｔ１ペプチド及びその組成物、並びにその作成方法
EP3834836A1 (en) 2006-04-10 2021-06-16 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and uses thereof
ES2606034T3 (es) 2006-09-28 2017-03-17 Merck Sharp & Dohme Corp. IL-10 pegilada para uso en el tratamiento de linfoma
US20080089875A1 (en) * 2006-10-13 2008-04-17 Zheng Cui Methods and compositions for the treatment of cancer
US20110268757A1 (en) 2008-12-03 2011-11-03 Institut Pasteur Use of phenol-soluble modulins for vaccine development
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
EP2505640A1 (en) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Vaccine compositions for birnavirus-borne diseases
EP3520810A3 (en) 2012-01-13 2019-11-06 Memorial Sloan-Kettering Cancer Center Immunogenic wt1 peptides and use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
AU2014207615B2 (en) 2013-01-15 2018-11-01 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
JP6257655B2 (ja) 2013-03-01 2018-01-10 アメリカ合衆国 末梢血から腫瘍反応性ｔ細胞の濃縮された集団を作製する方法
RU2679889C2 (ru) 2013-04-18 2019-02-14 Армо Байосайенсиз, Инк. Способы применения интерлейкина-10 для лечения заболеваний и расстройств
EP3010527B1 (en) 2013-06-17 2018-08-08 Armo Biosciences, Inc. Method for assessing protein identity and stability
MX2016005915A (es) 2013-11-11 2016-12-16 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
JP2017507950A (ja) 2014-02-27 2017-03-23 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法
AU2015256190B2 (en) 2014-05-05 2019-08-15 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
US10189777B2 (en) 2014-05-05 2019-01-29 Lycera Corporation Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease
CN106573072A (zh) 2014-06-02 2017-04-19 阿尔莫生物科技股份有限公司 降低血清胆固醇的方法
ES2941234T3 (es) 2014-10-22 2023-05-19 Armo Biosciences Inc Métodos de uso de la interleucina-10 para el tratamiento de enfermedades y trastornos
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
US10421751B2 (en) 2015-05-05 2019-09-24 Lycera Corporation Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
US20160361415A1 (en) 2015-05-28 2016-12-15 Armo Biosciences, Inc. Methods of Using Interleukin-10 for Treating Diseases and Disorders
CN107980042B (zh) 2015-06-11 2021-10-08 莱斯拉公司 用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物
EP3341012A4 (en) 2015-08-25 2019-03-20 Armo Biosciences, Inc. METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
US20210379106A1 (en) * 2018-06-14 2021-12-09 Lixte Biotechnology, Inc. Oxabicycloheptanes for enhancing car t cell function

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4902288A (en) * 1985-12-03 1990-02-20 Marylou Ingram Implantable immunotherapy system using stimulated cells
US4965195A (en) * 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US5041289A (en) * 1987-11-13 1991-08-20 Becton Dickinson And Company Method of purging residual tumor cells in vitro with lymphokine activated cytotoxic cells
WO1989007445A1 (en) * 1988-02-11 1989-08-24 Board Of Regents, The University Of Texas System Improved method for treatment of cancer with activated oncolytic leukocytes
US5032396A (en) * 1989-02-17 1991-07-16 Immunex Corporation IL-7 to stimulate platelet production

Also Published As

Publication number Publication date
IE912486A1 (en) 1992-01-29
ES2112860T3 (es) 1998-04-16
DE69128476D1 (de) 1998-01-29
JP3825467B2 (ja) 2006-09-27
DK0540599T3 (da) 1998-08-24
DE69128476T2 (de) 1998-07-23
FI930206A (fi) 1993-01-19
AU646881B2 (en) 1994-03-10
JPH05509093A (ja) 1993-12-16
EP0540599B1 (en) 1997-12-17
IL98957A (en) 2000-11-21
NO930243D0 (no) 1993-01-25
US5229115A (en) 1993-07-20
AU8287291A (en) 1992-02-18
FI105045B (fi) 2000-05-31
CA2087525A1 (en) 1992-01-27
ATE161180T1 (de) 1998-01-15
EP0540599A1 (en) 1993-05-12
IL98957A0 (en) 1992-07-15
GR3026358T3 (en) 1998-06-30
NZ239113A (en) 1997-07-27
CA2087525C (en) 2006-05-30
NO930243L (no) 1993-01-25
WO1992001459A1 (en) 1992-02-06

Similar Documents

Publication Publication Date Title
FI930206A (fi) Adoptiv immunoterapi med interleukin-7
FI953731A0 (fi) Menetelmä PRRS-viruksen viljelemiseksi ja sen käyttö rokotteissa
SE8005256L (sv) Framstellningsforfarande
DE69022290D1 (de) Lebende Impfstoffe.
IT8247649A0 (it) Dispositivo per realizzare colture di microorganismi
SE8000243L (sv) Typ ii-interferon och medel innehallande detsamma
DE69028320D1 (de) Illudin-analoge, verwendet als antitumormittel
ATE15693T1 (de) Zellkultur-verfahren.
DK372780A (da) Fremgangsmaade til propagering af humant hepatitis a virus
NO922422D0 (no) Matrise med adherent bundede celler, samt fremgangsmaate ved fremstilling av virus/virusantigener
DK0538330T3 (da) Beta-Alethin-anvendelse til celledyrkning og terapi
PT72015B (en) Process for preparing "invitro" cultures of hepatitis b virus
ATE4637T1 (de) Pentadecapeptid, verfahren zu seiner herstellung und immunisierendes mittel.
FR2589063B1 (fr) Procede de culture de babesia canis, application a la preparation d'antigenes et de vaccins, et antigenes et vaccins contre la piroplasmose
SE8005921L (sv) Nya foreningar med karcinostatisk och immunostimulerande aktivitet samt forfarande for framstellning derav
SE9403636D0 (sv) Vaccine preparation
IT1217825B (it) Procedimento ed impianto per la coltura di microorganismi
IT1094286B (it) Procedimento per favorire la crescita di microorganismi fotosintetici e organismi simili
JPS5550816A (en) Sterilization of culture medium for mushroom cultivation
Vilcek CELL SUBSTRATES FOR BIOLOGICALS OTHER THAN VACCINES
SU1566533A1 (ru) Способ изготовления вакцины против пастереллеза птиц
PL285546A1 (en) Biological culture medium for cell cultures and method of culturing human keratocytes as well as proteinous concentrate
DK197091A (da) Fremgangsmaade til fremstilling af proteiner med fviii aktivitet og/eller fviii derivater
JPS54138184A (en) Sterilizing method of fermenting culture medium

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: SANOFI

MA Patent expired